✓ Produto localizado
Medicamentos E Saúde
Medicamentos E Saúde
INVEGA SUSTENNA 50 MG ML SERINGA PREENCHIDA 0 5 ML SIMILAR
Invega- GTIN / EAN
- 7896212424092
- NCM
- 30049099
- CEST
- Não informado
- Conteúdo
- Não informado
Dados de produto preservados no idioma original.
INVEGA SUSTENNA 50 MG ML SERINGA PREENCHIDA 0 5 ML SIMILAR é fabricado pela Invega, na categoria Medicamentos E Saúde, com código de barras 7896212424092. Classificado no NCM 30049099 (Outros).
Fonte: SI5 Global · código registrado em Brasil · atualizado em 03/10/2026
Preço base (referência): R$ 1.549,99 — coletado em paguemenos.com.br em 03/10/2026, pode não estar atualizado
Classificação fiscal
- NCM
- 30049099Outros
Descrição do produto
O que é Invega Sustenna 50mg Suspensão Injetável com 1 Seringa?
Invega Sustenna 50mg é uma suspensão injetável de liberação prolongada indicada para o tratamento da esquizofrenia e prevenção da recorrência dos sintomas. O medicamento contém palmitato de paliperidona, que age como antipsicótico, equilibrando os níveis de dopamina e serotonina no cérebro. Invega também é indicado no tratamento do transtorno esquizoafetivo, podendo ser usado sozinho ou em combinação com outros medicamentos.
Conteúdo da embalagem: 1 seringa preenchida com 0,5 mL contendo 50mg de paliperidona.
Fabricado por: Janssen
Composição Invega Sustenna 50mg:
Princípio ativo: 78mg de palmitato de paliperidona, equivalente a 50mg de palliperidona
Excipientes: Polissorbato 20, macrogol, ácido cítrico monoidratado, fosfato de sódio dibásico, fosfato de sódio monobásico, hidróxido de sódio, água para injetáveis.
Para que serve Invega Sustenna 50mg?
Invega Sustenna 50mg é indicado para:
- Tratamento da esquizofrenia.
- Prevenção da recorrência dos sintomas da esquizofrenia.
- Tratamento do transtorno esquizoafetivo, em monoterapia ou como adjuvante a estabilizadores de humor ou antidepressivos.
Como devo usar Invega Sustenna 50mg?
O Invega Sustenna 50mg deve ser utilizado como dose de manutenção mensal após as doses iniciais recomendadas (150mg no primeiro dia e 100mg uma semana depois, ambas no músculo deltoide).
As doses mensais podem ser administradas no músculo deltoide ou glúteo, respeitando a dosagem indicada pelo médico, que pode variar entre 50 e 150 mg dependendo da tolerabilidade e eficácia individual.
Como funciona Invega Sustenna 50mg?
Invega Sustenna 50mg bloqueia os receptores de dopamina D2 e serotonina 5HT2A, ajudando a controlar os sintomas de esquizofrenia. A liberação prolongada proporciona controle contínuo dos sintomas.
Efeitos colaterais Invega Sustenna:
- Tontura.
- Aumento de peso.
- Insônia.
- Dor de cabeça.
- Taquicardia.
- Reações no local da injeção.
- Movimentos involuntários (discinesia).
Cuidados importantes:
- Invega Sustenna deve ser armazenado entre 15°C e 30°C, protegido da luz.
- Não administrar por via intravenosa ou subcutânea.
- Pode causar tontura, afetando a capacidade de operar máquinas ou dirigir.
Contraindicações:
- Hipersensibilidade ao palmitato de paliperidona ou a qualquer componente da fórmula.
- Contraindicado para pacientes com histórico de reação alérgica à risperidona.
- Pacientes com distúrbios cardíacos, como síndrome do QT longo, devem utilizar com cautela.
Ficha técnica
- Medicamento
- True
- MarcaPropria
- Não
- NumeroRegistroMS
- 1.1236.3398.004-9
- NomeSubstanciaPrincipioAtivo
- Paliperidoma
- DescricaoBula
- %0A%09%09%09%09%09%09%3Ch2%3ELaborat%26%23xF3%3Brio%3C%2Fh2%3E%0A%3Cp%3Ejanssen%3C%2Fp%3E%0A%3Ch2%3E%20Apresenta%26%23xE7%3B%26%23xE3%3Bo%20INVEGA%20%3C%2Fh2%3E%0A%3Cp%3EComprimidos%20revestidos%20de%20libera%26%23xE7%3B%26%23xE3%3Bo%20prolongada%20de%203%2C%206%20e%209%20mg%20em%20embalagens%20%20com%207%20e%2028%20comprimidos.%3C%2Fp%3E%0A%3Ch2%3E%20INVEGA%20%26%23x2013%3B%20Indica%26%23xE7%3B%26%23xF5%3Bes%20%3C%2Fh2%3E%0A%3Cp%3EInvega%20%26%23xE9%3B%20indicado%20para%20o%20tratamento%20da%20esquizofrenia%2C%20incluindo%20tratamento%20agudo%20e%20preven%26%23xE7%3B%26%23xE3%3Bo%20de%20recorr%26%23xEA%3Bncia.%3C%2Fp%3E%0A%3Ch2%3E%20Contra%20indica%26%23xE7%3B%26%23xF5%3Bes%20de%20INVEGA%20%3C%2Fh2%3E%0A%3Cp%3EInvega%20%26%23xE9%3B%20contra-indicado%20em%20pacientes%20com%20hipersensibilidade%20conhecida%20%26%23xE0%3B%20paliperidona%20ou%20a%20qualquer%20componente%20da%20formula%26%23xE7%3B%26%23xE3%3Bo.%20Invega%20%26%23xE9%3B%20contra-indicado%20em%20pacientes%20com%20conhecida%20hipersensibilidade%20%26%23xE0%3B%20risperidona%2C%20uma%20vez%20que%20a%20paliperidona%20corresponde%20a%20um%20metab%26%23xF3%3Blito%20ativo%20da%20risperidona.%3C%2Fp%3E%0A%20%20%20%20%20%20%20%20%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%20%20%20%20%20%20%20%20%20%20%20%20%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%20%20%20%20%20%20%20%20%3C%2Famp-ad%3E%0A%3Ch2%3EAdvert%26%23xEA%3Bncias%3C%2Fh2%3E%0A%3Cp%3ES%26%23xED%3Bndrome%20neurol%26%23xE9%3Bptica%20maligna%20%20A%20ocorr%26%23xEA%3Bncia%20de%20s%26%23xED%3Bndrome%20neurol%26%23xE9%3Bptica%20maligna%20caracterizada%20%20por%20hipertermia%2C%20rigidez%20muscular%2C%20instabilidade%20auton%26%23xF4%3Bmica%2C%20%20altera%26%23xE7%3B%26%23xE3%3Bo%20da%20consci%26%23xEA%3Bncia%20e%20n%26%23xED%3Bveis%20elevados%20de%20creatina%20fosfoquinase%20%20t%26%23xEA%3Bm%20sido%20relatada%20com%20f%26%23xE1%3Brmacos%20antipsic%26%23xF3%3Bticos%2C%20%20incluindo%20a%20paliperidona.%20Sinais%20cl%26%23xED%3Bnicos%20adicionais%20podem%20incluir%20%20mioglobin%26%23xFA%3Bria%20(rabdomi%26%23xF3%3Blise)%20e%20insufi%20ci%26%23xEA%3Bncia%20renal%20aguda.%20%20Se%20o%20paciente%20desenvolver%20sinais%20ou%20sintomas%20indicativos%20de%20%20s%26%23xED%3Bndrome%20neurol%26%23xE9%3Bptica%20maligna%2C%20todos%20os%20antipsic%26%23xF3%3Bticos%2C%20incluindo%20%20Invega%2C%20devem%20ser%20descontinuados.%20%20Discinesia%20tardia%20%20F%26%23xE1%3Brmacos%20com%20propriedades%20antagonistas%20de%20receptor%20dopamin%26%23xE9%3Brgico%20%20t%26%23xEA%3Bm%20sido%20associados%20%26%23xE0%3B%20indu%26%23xE7%3B%26%23xE3%3Bo%20de%20discinesia%20tardia%20%20caracterizada%20por%20movimentos%20involunt%26%23xE1%3Brios%2C%20r%26%23xED%3Btmicos%2C%20predominantemente%20%20da%20l%26%23xED%3Bngua%20e%2Fou%20da%20face.%20Se%20surgirem%20sinais%20ou%20%20sintomas%20de%20discinesia%20tardia%2C%20a%20descontinua%26%23xE7%3B%26%23xE3%3Bo%20de%20todos%20os%20f%26%23xE1%3Brmacos%20antipsic%26%23xF3%3Bticos%2C%20incluindo%20Invega%2C%20deve%20ser%20considerada.%20%20Intervalo%20QT%20%20Assim%20como%20outros%20antipsic%26%23xF3%3Bticos%2C%20deve-se%20ter%20cautela%20quando%20%20Invega%26%23x99%3B%20%26%23xE9%3B%20prescrito%20a%20pacientes%20com%20hist%26%23xF3%3Brico%20de%20arritmias%20%20card%26%23xED%3Bacas%2C%20em%20pacientes%20com%20s%26%23xED%3Bndrome%20cong%26%23xEA%3Bnita%20do%20prolongamento%20%20do%20intervalo%20QT%20e%20em%20uso%20concomitante%20com%20medicamentos%20%20que%20conhecidamente%20prolongam%20o%20intervalo%20QT.%20%20Hiperglicemia%20%20Casos%20raros%20de%20eventos%20adversos%20relacionados%20%26%23xE0%3B%20glicose%20%20foram%20relatados%20em%20estudos%20cl%26%23xED%3Bnicos%20com%20Invega%26%23x99%3B%20.%20Recomenda-%20%20se%20o%20monitoramento%20cl%26%23xED%3Bnico%20apropriado%20em%20pacientes%20%20diab%26%23xE9%3Bticos%20e%20em%20pacientes%20com%20fatores%20de%20risco%20para%20o%20desenvolvimento%20%20de%20diabetes%20mellitus.%20%20Hipotens%26%23xE3%3Bo%20ortost%26%23xE1%3Btica%20%20A%20paliperidona%20pode%20induzir%20hipotens%26%23xE3%3Bo%20ortost%26%23xE1%3Btica%20em%20alguns%20%20pacientes%20em%20fun%26%23xE7%3B%26%23xE3%3Bo%20de%20sua%20atividade%20de%20bloqueador%20alfa.%20Invega%20%20%26%23x99%3B%20deve%20ser%20usado%20com%20cautela%20em%20pacientes%20com%20hist%26%23xF3%3Bria%20%20de%20doen%26%23xE7%3Ba%20cardiovascular%20(como%20por%20exemplo%2C%20insufi%20ci%26%23xEA%3Bncia%20%20card%26%23xED%3Baca%2C%20infarto%20ou%20isquemia%20do%20mioc%26%23xE1%3Brdio%2C%20anormalidades%20da%20condu%26%23xE7%3B%26%23xE3%3Bo)%2C%20doen%26%23xE7%3Ba%20vascular%20cerebral%20ou%20condi%26%23xE7%3B%26%23xF5%3Bes%20que%20%20predisponham%20o%20paciente%20%26%23xE0%3B%20hipotens%26%23xE3%3Bo%20(como%20por%20exemplo%2C%20%20desidrata%26%23xE7%3B%26%23xE3%3Bo%2C%20hipovolemia%20e%20tratamento%20com%20medicamentos%20%20anti-hipertensivos).%20%20Crises%20epil%26%23xE9%3Bpticas%20%20Da%20mesma%20forma%20que%20outros%20antipsic%26%23xF3%3Bticos%2C%20Invega%26%23x99%3B%20deve%20%20ser%20usado%20com%20cautela%20em%20pacientes%20com%20hist%26%23xF3%3Bria%20de%20crises%20%20epil%26%23xE9%3Bpticas%20ou%20outras%20condi%26%23xE7%3B%26%23xF5%3Bes%20que%20reduzem%20potencialmente%20%20o%20limiar%20convulsivo.%20%20Potencial%20para%20obstru%26%23xE7%3B%26%23xE3%3Bo%20gastrintestinal%20%20Uma%20vez%20que%20o%20comprimido%20de%20Invega%26%23x99%3B%20n%26%23xE3%3Bo%20se%20deforma%20e%20n%26%23xE3%3Bo%20%20altera%20sua%20forma%20no%20trato%20gastrintestinal%2C%20Invega%26%23x99%3B%20n%26%23xE3%3Bo%20deve%20%20ser%20administrado%20a%20pacientes%20com%20estreitamento%20gastrintestinal%20%20grave%20preexistente%20(patol%26%23xF3%3Bgico%20ou%20iatrog%26%23xEA%3Bnico)%20ou%20em%20pacientes%20%20com%20disfagia%20ou%20difi%20culdade%20signifi%20cante%20para%20deglutir%20comprimidos.%20%20Tem%20havido%20relatos%20raros%20de%20sintomas%20de%20obstru%26%23xE7%3B%26%23xE3%3Bo%20em%20%20pacientes%20com%20hist%26%23xF3%3Bria%20de%20estreitamento%20associado%20%26%23xE0%3B%20ingest%26%23xE3%3Bo%20%20de%20f%26%23xE1%3Brmacos%20em%20formula%26%23xE7%3B%26%23xF5%3Bes%20n%26%23xE3%3Bo%20deform%26%23xE1%3Bveis%20de%20libera%26%23xE7%3B%26%23xE3%3Bo%20%20controlada.%20Devido%20ao%20desenho%20da%20forma%20farmac%26%23xEA%3Butica%20de%20libera%26%23xE7%3B%26%23xE3%3Bo%20prolongada%2C%20Invega%26%23x99%3B%20s%26%23xF3%3B%20deve%20ser%20usado%20em%20pacientes%20%20capazes%20de%20deglutir%20o%20comprimido%20inteiro.%20%20Pacientes%20idosos%20com%20dem%26%23xEA%3Bncia%20%20Invega%26%23x99%3B%20n%26%23xE3%3Bo%20foi%20estudado%20nessa%20popula%26%23xE7%3B%26%23xE3%3Bo%20de%20pacientes%2C%20%20desta%20forma%20o%20medicamento%20n%26%23xE3%3Bo%20%26%23xE9%3B%20recomendado%20para%20pacientes%20%20idosos%20com%20dem%26%23xEA%3Bncia.%20%20Mortalidade%20geral%20%20Em%20uma%20meta-an%26%23xE1%3Blise%20de%2017%20estudos%20cl%26%23xED%3Bnicos%20controlados%2C%20%20pacientes%20idosos%20com%20dem%26%23xEA%3Bncia%20tratados%20com%20outros%20f%26%23xE1%3Brmacos%20%20antipsic%26%23xF3%3Bticos%20at%26%23xED%3Bpicos%2C%20incluindo%20a%20risperidona%2C%20aripiprazol%2C%20%20olanzapina%20e%20quetiapina%2C%20tiveram%20um%20risco%20aumentado%20de%20%20mortalidade%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20ao%20placebo.%20%20Eventos%20adversos%20vascular%20cerebral%20%20Em%20estudos%20cl%26%23xED%3Bnicos%20controlados%20com%20placebo%20em%20pacientes%20%20idosos%20com%20dem%26%23xEA%3Bncia%2C%20tratados%20com%20f%26%23xE1%3Brmacos%20antipsic%26%23xF3%3Bticos%20%20at%26%23xED%3Bpicos%2C%20incluindo%20a%20risperidona%2C%20aripiprazol%20e%20olanzapina%2C%20houve%20%20uma%20incid%26%23xEA%3Bncia%20maior%20de%20eventos%20adversos%20vascular%20cerebral%20%20(acidente%20vascular%20cerebral%20e%20epis%26%23xF3%3Bdios%20de%20isquemia%20transit%26%23xF3%3Bria)%2C%20%20incluindo%20casos%20fatais%2C%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20ao%20placebo.%20%20Doen%26%23xE7%3Ba%20de%20Parkinson%20e%20dem%26%23xEA%3Bncia%20com%20corpos%20de%20Lewy%20%20O%20m%26%23xE9%3Bdico%20deve%20pesar%20os%20riscos%20em%20rela%26%23xE7%3B%26%23xE3%3Bo%20aos%20benef%26%23xED%3Bcios%20ao%20%20prescrever%20antipsic%26%23xF3%3Bticos%2C%20incluindo%20Invega%26%23x99%3B%2C%20para%20pacientes%20%20com%20doen%26%23xE7%3Ba%20de%20Parkinson%20ou%20dem%26%23xEA%3Bncia%20com%20corpos%20de%20Lewy%2C%20%20uma%20vez%20que%20ambos%20os%20grupos%20podem%20estar%20sob%20risco%20aumentado%20%20de%20desenvolver%20s%26%23xED%3Bndrome%20neurol%26%23xE9%3Bptica%20maligna%2C%20assim%20%20como%20de%20ter%20uma%20sensibilidade%20aumentada%20a%20medicamentos%20%20antipsic%26%23xF3%3Bticos.%20A%20manifesta%26%23xE7%3B%26%23xE3%3Bo%20dessa%20sensibilidade%20aumentada%20%20pode%20incluir%20confus%26%23xE3%3Bo%2C%20embotamento%2C%20instabilidade%20postural%20%20com%20quedas%20frequentes%2C%20al%26%23xE9%3Bm%20dos%20sintomas%20extrapiramidais.%20%20Priapismo%20%20Tem%20sido%20relatado%20que%20f%26%23xE1%3Brmacos%20com%20efeitos%20de%20bloqueio%20alfaadren%26%23xE9%3Brgico%20%20induzem%20o%20priapismo.%20Embora%20nenhum%20caso%20de%20%20priapismo%20tenha%20sido%20relatado%20nos%20estudos%20cl%26%23xED%3Bnicos%20com%20Invega%20%20%26%23x99%3B%2C%20a%20paliperidona%20compartilha%20essa%20atividade%20farmacol%26%23xF3%3Bgica%20%20e%2C%20portanto%2C%20pode%20estar%20associada%20a%20esse%20risco.%20%20Controle%20da%20temperatura%20corporal%20%20A%20interrup%26%23xE7%3B%26%23xE3%3Bo%20da%20capacidade%20do%20organismo%20de%20reduzir%20a%20%20temperatura%20corporal%20foi%20atribu%26%23xED%3Bda%20a%20agentes%20antipsic%26%23xF3%3Bticos.%20%20Recomenda-se%20cuidado%20apropriado%20ao%20prescrever%20Invega%26%23x99%3B%20para%20pacientes%20que%20ir%26%23xE3%3Bo%20se%20expor%20a%20condi%26%23xE7%3B%26%23xF5%3Bes%20que%20possam%20%20contribuir%20para%20o%20aumento%20da%20temperatura%20corporal%2C%20como%20por%20%20exemplo%20exerc%26%23xED%3Bcio%20extenuante%2C%20exposi%26%23xE7%3B%26%23xE3%3Bo%20ao%20calor%20extremo%2C%20%20uso%20de%20medica%26%23xE7%3B%26%23xE3%3Bo%20concomitante%20com%20atividade%20anticolin%26%23xE9%3Brgica%2C%20%20ou%20sujeito%20a%20desidrata%26%23xE7%3B%26%23xE3%3Bo.%20%20Efeito%20antiem%26%23xE9%3Btico%20%20Um%20efeito%20antiem%26%23xE9%3Btico%20foi%20observado%20em%20estudos%20pr%26%23xE9%3B-cl%26%23xED%3Bnicos%20%20com%20a%20paliperidona.%20Esse%20efeito%2C%20se%20ocorrer%20em%20seres%20humanos%2C%20%20pode%20mascarar%20os%20sinais%20e%20sintomas%20de%20dose%20excessiva%20%20com%20certos%20f%26%23xE1%3Brmacos%20ou%20de%20condi%26%23xE7%3B%26%23xF5%3Bes%20tais%20como%20obstru%26%23xE7%3B%26%23xE3%3Bo%20%20intestinal%2C%20s%26%23xED%3Bndrome%20de%20Reye%20e%20tumor%20cerebral.%20%20Efeitos%20sobre%20a%20capacidade%20de%20dirigir%20ve%26%23xED%3Bculos%20e%20utilizar%20%20m%26%23xE1%3Bquinas%20%20Invega%26%23x99%3B%20pode%20interferir%20com%20as%20atividades%20que%20requerem%20%20alerta%20mental%20e%20pode%20ocasionar%20efeitos%20visuais%20(veja%20o%20item%20%20%26%23x93%3BRea%26%23xE7%3B%26%23xF5%3Bes%20Adversas%26%23x94%3B).%20%20Durante%20o%20tratamento%2C%20o%20paciente%20n%26%23xE3%3Bo%20deve%20dirigir%20ve%26%23xED%3Bculos%20%20ou%20operar%20m%26%23xE1%3Bquinas%2C%20pois%20sua%20habilidade%20e%20aten%26%23xE7%3B%26%23xE3%3Bo%20%20podem%20estar%20prejudicadas.%3C%2Fp%3E%0A%3Ch2%3EIntera%26%23xE7%3B%26%23xF5%3Bes%20medicamentosas%20de%20INVEGA%3C%2Fh2%3E%0A%3Cp%3ERecomenda-se%20cautela%20ao%20prescrever%20Invega%20com%20medicamentos%20%20conhecidos%20por%20prolongar%20o%20intervalo%20QT.%20%20Potencial%20de%20Invega%20afetar%20outros%20f%26%23xE1%3Brmacos%20%20N%26%23xE3%3Bo%20%26%23xE9%3B%20esperado%20que%20a%20paliperidona%20cause%20intera%26%23xE7%3B%26%23xF5%3Bes%20farmacocin%26%23xE9%3Bticas%20%20clinicamente%20importantes%20com%20f%26%23xE1%3Brmacos%20que%20s%26%23xE3%3Bo%20%20metabolizados%20pelas%20isoenzimas%20do%20citocromo%20P-450.%20Estudos%20%20in%20vitro%20em%20microssomas%20hep%26%23xE1%3Bticos%20humanos%20mostraram%20que%20%20a%20paliperidona%20n%26%23xE3%3Bo%20inibe%20de%20forma%20substancial%20o%20metabolismo%20%20de%20f%26%23xE1%3Brmacos%20metabolizados%20pelas%20isoenzimas%20do%20citocromo%20%20P-450%2C%20incluindo%20CYP1A2%2C%20CYP2A6%2C%20CYP2C8%2F9%2F10%2C%20CYP2D6%2C%20%20CYP2E1%2C%20CYP3A4%20e%20CYP3A5.%20Portanto%2C%20n%26%23xE3%3Bo%20se%20espera%20que%20%20a%20paliperidona%20iniba%2C%20de%20forma%20clinicamente%20relevante%2C%20a%20depura%26%23xE7%3B%26%23xE3%3Bo%20%20de%20f%26%23xE1%3Brmacos%20que%20s%26%23xE3%3Bo%20metabolizados%20por%20essas%20vias%20%20metab%26%23xF3%3Blicas.%20N%26%23xE3%3Bo%20%26%23xE9%3B%20esperado%2C%20tamb%26%23xE9%3Bm%2C%20que%20a%20paliperidona%20%20tenha%20propriedades%20indutoras%20de%20enzimas.%20%20Em%20altas%20concentra%26%23xE7%3B%26%23xF5%3Bes%2C%20a%20paliperidona%20%26%23xE9%3B%20um%20fraco%20inibidor%20da%20%20glicoprote%26%23xED%3Bna-P%20(P-gp).%20N%26%23xE3%3Bo%20h%26%23xE1%3B%20dados%20in%20vivo%20dispon%26%23xED%3Bveis%20e%20a%20%20relev%26%23xE2%3Bncia%20cl%26%23xED%3Bnica%20%26%23xE9%3B%20desconhecida.%20%20Devido%20aos%20efeitos%20prim%26%23xE1%3Brios%20da%20paliperidona%20sobre%20o%20sistema%20%20nervoso%20central%2C%20Invega%26%23x99%3B%20deve%20ser%20usado%20com%20cautela%20em%20%20combina%26%23xE7%3B%26%23xE3%3Bo%20com%20outros%20f%26%23xE1%3Brmacos%20de%20a%26%23xE7%3B%26%23xE3%3Bo%20central%20e%20%26%23xE1%3Blcool.%20A%20%20paliperidona%20pode%20antagonizar%20o%20efeito%20da%20levodopa%20e%20outros%20%20agonistas%20dopamin%26%23xE9%3Brgicos.%20%20Devido%20ao%20seu%20potencial%20para%20induzir%20hipotens%26%23xE3%3Bo%20ortost%26%23xE1%3Btica%2C%20%20pode%20ser%20observado%20um%20efeito%20aditivo%20quando%20Invega%26%23x99%3B%20%26%23xE9%3B%20%20administrado%20com%20outros%20agentes%20terap%26%23xEA%3Buticos%20que%20possuem%20%20esse%20potencial.%20%20Potencial%20para%20outros%20f%26%23xE1%3Brmacos%20afetarem%20Invega%26%23x99%3B%20%20A%20paliperidona%20n%26%23xE3%3Bo%20%26%23xE9%3B%20um%20substrato%20da%20CYP1A2%2C%20CYP2A6%2C%20%20CYP2C9%2C%20CYP2C19%20e%20CYP3A5.%20Isso%20sugere%20que%20n%26%23xE3%3Bo%20%26%23xE9%3B%20prov%26%23xE1%3Bvel%20%20a%20ocorr%26%23xEA%3Bncia%20de%20intera%26%23xE7%3B%26%23xE3%3Bo%20com%20inibidores%20ou%20indutores%20%20dessas%20isoenzimas.%20Embora%20estudos%20in%20vitro%20indiquem%20que%20a%20%20CYP2D6%20e%20a%20CYP3A4%20podem%20estar%20minimamente%20envolvidas%20%20no%20metabolismo%20da%20paliperidona%2C%20n%26%23xE3%3Bo%20h%26%23xE1%3B%20indica%26%23xE7%3B%26%23xF5%3Bes%20in%20vitro%20%20nem%20in%20vivo%20de%20que%20essas%20isoenzimas%20tenham%20um%20papel%20signifi%20cante%20no%20metabolismo%20da%20paliperidona.%20Estudos%20in%20vitro%20%20demonstraram%20que%20a%20paliperidona%20%26%23xE9%3B%20um%20substrato%20da%20glicoprote%26%23xED%3Bna%20%20P.%20%20A%20paliperidona%20%26%23xE9%3B%20metabolizada%20com%20extens%26%23xE3%3Bo%20limitada%20pela%20%20CYP2D6%20(veja%20Propriedades%20Farmacocin%26%23xE9%3Bticas%3A%20metabolismo%20%20e%20elimina%26%23xE7%3B%26%23xE3%3Bo).%20N%26%23xE3%3Bo%20foram%20observados%20efeitos%20clinicamente%20%20relevantes%20sobre%20a%20farmacocin%26%23xE9%3Btica%20da%20paliperidona%2C%20em%20um%20%20estudo%20de%20intera%26%23xE7%3B%26%23xE3%3Bo%20em%20indiv%26%23xED%3Bduos%20saud%26%23xE1%3Bveis%20no%20qual%20Invega%20%20%26%23x99%3B%20foi%20administrado%20concomitantemente%20com%20paroxetina%2C%20%20um%20potente%20inibidor%20da%20CYP2D6.%20%20A%20co-adminstra%26%23xE7%3B%26%23xE3%3Bo%20de%20Invega%26%23x99%3B%20uma%20vez%20ao%20dia%20com%20carbamazepina%20%20200%20mg%20duas%20vezes%20ao%20dia%20causou%20uma%20diminui%26%23xE7%3B%26%23xE3%3Bo%20%20de%20aproximadamente%2037%25%20no%20estado%20de%20equil%26%23xED%3Bbrio%20m%26%23xE9%3Bdio%20da%20%20Cm%26%23xE1%3Bx%20e%20AUC%20da%20paliperidona.%20Esta%20diminui%26%23xE7%3B%26%23xE3%3Bo%20%26%23xE9%3B%20causada%20por%20%20um%20grau%20substancial%2C%20por%20um%20aumento%20de%2035%25%20na%20depura%26%23xE7%3B%26%23xE3%3Bo%20%20renal%20da%20paliperidona%20provavelmente%20como%20um%20resultado%20da%20%20indu%26%23xE7%3B%26%23xE3%3Bo%20da%20glicoprote%26%23xED%3Bna%20P%20renal%20pela%20carbamazepina.%20Uma%20%20menor%20diminui%26%23xE7%3B%26%23xE3%3Bo%20na%20quantidade%20de%20droga%20excretada%20inalterada%20%20na%20urina%20sugere%20que%20h%26%23xE1%3B%20um%20pequeno%20efeito%20sobre%20o%20%20metabolismo%20da%20CYP%20ou%20biodisponibilidade%20da%20paliperidona%20nifi%20cante%20no%20metabolismo%20da%20paliperidona.%20Estudos%20in%20vitro%20%20demonstraram%20que%20a%20paliperidona%20%26%23xE9%3B%20um%20substrato%20da%20glicoprote%26%23xED%3Bna%20P.%20%20%20A%20paliperidona%20%26%23xE9%3B%20metabolizada%20com%20extens%26%23xE3%3Bo%20limitada%20pela%20CYP2D6%20(veja%20Propriedades%20Farmacocin%26%23xE9%3Bticas%3A%20metabolismo%20e%20elimina%26%23xE7%3B%26%23xE3%3Bo).%20N%26%23xE3%3Bo%20foram%20observados%20efeitos%20clinicamente%20%20relevantes%20sobre%20a%20farmacocin%26%23xE9%3Btica%20da%20paliperidona%2C%20em%20um%20estudo%20de%20intera%26%23xE7%3B%26%23xE3%3Bo%20em%20indiv%26%23xED%3Bduos%20saud%26%23xE1%3Bveis%20no%20qual%20Invega%20%26%23x99%3B%20foi%20administrado%20concomitantemente%20com%20paroxetina%2C%20um%20potente%20inibidor%20da%20CYP2D6.%20%20A%20co-adminstra%26%23xE7%3B%26%23xE3%3Bo%20de%20Invega%26%23x99%3B%20uma%20vez%20ao%20dia%20com%20carbamazepina%20200%20mg%20duas%20vezes%20ao%20dia%20causou%20uma%20diminui%26%23xE7%3B%26%23xE3%3Bo%20de%20aproximadamente%2037%25%20no%20estado%20de%20equil%26%23xED%3Bbrio%20m%26%23xE9%3Bdio%20da%20Cm%26%23xE1%3Bx%20e%20AUC%20da%20paliperidona.%20Esta%20diminui%26%23xE7%3B%26%23xE3%3Bo%20%26%23xE9%3B%20causada%20por%20um%20grau%20substancial%2C%20por%20um%20aumento%20de%2035%25%20na%20depura%26%23xE7%3B%26%23xE3%3Bo%20%20renal%20da%20paliperidona%20provavelmente%20como%20um%20resultado%20da%20indu%26%23xE7%3B%26%23xE3%3Bo%20da%20glicoprote%26%23xED%3Bna%20P%20renal%20pela%20carbamazepina.%20Uma%20menor%20diminui%26%23xE7%3B%26%23xE3%3Bo%20na%20quantidade%20de%20droga%20excretada%20inalterada%20na%20urina%20sugere%20que%20h%26%23xE1%3B%20um%20pequeno%20efeito%20sobre%20o%20metabolismo%20da%20CYP%20ou%20biodisponibilidade%20da%20paliperidona.%3C%2Fp%3E%0A%3Ch2%3ERea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20%2F%20efeitos%20colaterais%20de%20INVEGA%3C%2Fh2%3E%0A%3Cp%3EDados%20de%20estudos%20cl%26%23xED%3Bnicos%20%20A%20seguran%26%23xE7%3Ba%20de%20Invega%20foi%20avaliada%20em%201205%20pacientes%20com%20esquizofrenia%20que%20participaram%20em%203%20estudos%20cl%26%23xED%3Bnicos%20de%20dose%20fixa%2C%20duplo-cegos%2C%20controlados%20com%20placebo%2C%20de%206%20semanas%20de%20dura%26%23xE7%3B%26%23xE3%3Bo.%20A%20informa%26%23xE7%3B%26%23xE3%3Bo%20apresentada%20a%20seguir%20para%20os%20pacientes%20tratados%20com%20Invega%20%26%23xE9%3B%20baseada%20nos%20dados%20%20agrupados%20de%20pacientes%20que%20receberam%20Invega%20na%20dose%20di%26%23xE1%3Bria%20recomendada%20de%203%2C%206%2C%209%20ou%2012%20mg.%20Os%20termos%20para%20sistemas%20corporais%20e%20evento%20adverso%2Frea%26%23xE7%3B%26%23xE3%3Bo%20adversa%20s%26%23xE3%3Bo%20baseados%20no%20dicion%26%23xE1%3Brio%20MedDRA.%20%20Dados%20de%20estudos%20cl%26%23xED%3Bnicos%3A%20Eventos%20adversos%20em%20estudos%20de%20curta-dura%26%23xE7%3B%26%23xE3%3Bo%2C%20com%20dose-fi%20xa%2C%20controlados%20com%20placebo.%20%20A%20Tabela%201%20mostra%20todos%20os%20eventos%20adversos%20emergentes%20durante%20o%20tratamento%2C%20independente%20da%20causalidade%2C%20com%20incid%26%23xEA%3Bncia%20%3D1%25%20dos%20pacientes%20tratados%20com%20Invega%20nesses%20estudos%2C%20e%20para%20os%20quais%20a%20incid%26%23xEA%3Bncia%20nos%20pacientes%20tratados%20com%20Invega%20foi%20maior%20que%20nos%20pacientes%20tratados%20com%20placebo.%20%20Tabela%201%3A%20Eventos%20adversos%20emergentes%20do%20tratamento%2C%20independente%20da%20causalidade%2C%20relatados%20por%20%26gt%3B%3D%201%25%20dos%20pacientes%20com%20esquizofrenia%20em%20qualquer%20grupo%20Invega%20e%20que%20ocorreram%20em%20incid%26%23xEA%3Bncia%20maior%20que%20no%20grupo%20placebo%20nos%203%20estudos%20cl%26%23xED%3Bnicos%20de%20dose%20fi%20xa%2C%20duplo-cegos%2C%20controlados%20com%20placebo%2C%20de%206%20semanas%20de%20dura%26%23xE7%3B%26%23xE3%3Bo.%20%20%20%20Sistema%20corporal%20ou%20classe%20de%20%26%23xF3%3Brg%26%23xE3%3Bo%20Placebo%203%20mg%206%20mg%209%20mg%2012%20mg%20%20(N%3D355)%20(N%3D127)%20(N%3D235)%20(N%3D246)%20(N%3D242)%20%20n%20(%25)%20n%20(%25)%20n%20(%25)%20n%20(%25)%20n%20(%25)%20%20Transtornos%20card%26%23xED%3Bacos%20%20Bloqueio%20atrioventricular%20de%201.%26%23xBA%3B%20grau%205%20(1%2C4)%202%20(1%2C6)%200%206%20(2%2C4)%202%20(0%2C8)%20%20Bradicardia%203%20(0%2C8)%200%203%20(1%2C3)%203%20(1%2C2)%204%20(1%2C7)%20%20Bloqueio%20de%20ramo%206%20(1%2C7)%204%20(3%2C1)%203%20(1%2C3)%207%20(2%2C8)%201%20(0%2C4)%20%20Palpita%26%23xE7%3B%26%23xF5%3Bes%200%202%20(1%2C6)%202%20(0%2C9)%200%203%20(1%2C2)%20%20Arritmia%20sinusal%200%203%20(2%2C4)%202%20(0%2C9)%202%20(0%2C8)%201%20(0%2C4)%20%20Taquicardia%20sinusal%2015%20(4%2C2)%2011%20(8%2C7)%209%20(3%2C8)%2010%20(4%2C1)%2017%20(7%2C0)%20%20Taquicardia%2010%20(2%2C8)%203%20(2%2C4)%2017%20(7%2C2)%2018%20(7%2C3)%2018%20(7%2C4)%20%20%20%20Sistema%20corporal%20ou%20classe%20de%20%26%23xF3%3Brg%26%23xE3%3Bo%20Placebo%203%20mg%206%20mg%209%20mg%2012%20mg%20%20(N%3D355)%20(N%3D127)%20(N%3D235)%20(N%3D246)%20(N%3D242)%20%20n%20(%25)%20n%20(%25)%20n%20(%25)%20n%20(%25)%20n%20(%25)%20%20Transtornos%20oculares%20%20Olho%20seco%200%202%20(1%2C6)%200%201%20(0%2C4)%201%20(0%2C4)%20%20Rota%26%23xE7%3B%26%23xE3%3Bo%20ocular%200%200%200%205%20(2%2C0)%200%20%20Vis%26%23xE3%3Bo%20borrada%204%20(1%2C1)%201%20(0%2C8)%201%20(0%2C4)%200%205%20(2%2C1)%20%20Transtornos%20gastrintestinais%20%20Dor%20abdominal%203%20(0%2C8)%200%204%20(1%2C7)%202%20(0%2C8)%202%20(0%2C8)%20%20Dor%20abdominal%20alta%202%20(0%2C6)%201%20(0%2C8)%206%20(2%2C6)%205%20(2%2C0)%204%20(1%2C7)%20%20Diarr%26%23xE9%3Bia%208%20(2%2C3)%201%20(0%2C8)%202%20(0%2C9)%203%20(1%2C2)%206%20(2%2C5)%20%20Transtornos%20gastrintestinais%20%20Boca%20seca%202%20(0%2C6)%203%20(2%2C4)%208%20(3%2C4)%202%20(0%2C8)%207%20(2%2C9)%20%20Dispepsia%2014%20(3%2C9)%203%20(2%2C4)%206%20(2%2C6)%205%20(2%2C0)%2012%20(5%2C0)%20%20N%26%23xE1%3Busea%2019%20(5%2C4)%208%20(6%2C3)%209%20(3%2C8)%2010%20(4%2C1)%2010%20(4%2C1)%20%20Hipersecre%26%23xE7%3B%26%23xE3%3Bo%20salivar%201%20(0%2C3)%200%201%20(0%2C4)%203%20(1%2C2)%2010%20(4%2C1)%20%20Desconforto%20estomacal%201%20(0%2C3)%202%20(1%2C6)%203%20(1%2C3)%201%20(0%2C4)%202%20(0%2C8)%20%20Dor%20de%20dente%204%20(1%2C1)%202%20(1%2C6)%205%20(2%2C1)%206%20(2%2C4)%205%20(2%2C1)%20%20V%26%23xF4%3Bmito%2017%20(4%2C8)%202%20(1%2C6)%206%20(2%2C6)%209%20(3%2C7)%2012%20(5%2C0)%20%20Transtornos%20gerais%20%20Astenia%203%20(0%2C8)%202%20(1%2C6)%201%20(0%2C4)%205%20(2%2C0)%205%20(2%2C1)%20%20Fadiga%205%20(1%2C4)%202%20(1%2C6)%202%20(0%2C9)%204%20(1%2C6)%205%20(2%2C1)%20%20Pirexia%204%20(1%2C1)%201%20(0%2C8)%201%20(0%2C4)%205%20(2%2C0)%204%20(1%2C7)%20%20Infec%26%23xE7%3B%26%23xF5%3Bes%20e%20inflama%26%23xE7%3B%26%23xF5%3Bes%20%20Bronquite%201%20(0%2C3)%200%203%20(1%2C3)%201%20(0%2C4)%202%20(0%2C8)%20%20Nasofaringite%2010%20(2%2C8)%204%20(3%2C1)%205%20(2%2C1)%204%20(1%2C6)%206%20(2%2C5)%20%20Rinite%201%20(0%2C3)%200%203%20(1%2C3)%200%201%20(0%2C4)%20%20Infec%26%23xE7%3B%26%23xF5%3Bes%20e%20inflama%26%23xE7%3B%26%23xF5%3Bes%20%20Infec%26%23xE7%3B%26%23xE3%3Bo%20vias%20a%26%23xE9%3Breas%20superiores%202%20(0%2C6)%201%20(0%2C8)%202%20(0%2C9)%203%20(1%2C2)%202%20(0%2C8)%20%20Infec%26%23xE7%3B%26%23xE3%3Bo%20viral%201%20(0%2C3)%200%201%20(0%2C4)%202%20(0%2C8)%203%20(1%2C2)%20%20Ferimento%2C%20envenenamento%20e%20%20complica%26%23xE7%3B%26%23xF5%3Bes%20de%20procedimento%20%20Queda%201%20(0%2C3)%200%203%20(1%2C3)%200%200%20%20Exames%20%20Aumento%20de%20alanina%20aminotransferase%204%20(1%2C1)%201%20(0%2C8)%204%20(1%2C7)%202%20(0%2C8)%202%20(0%2C8)%20%20Aumento%20de%20creatina%20fosfoquinase%205%20(1%2C4)%201%20(0%2C8)%204%20(1%2C7)%200%201%20(0%2C4)%20%20Aumento%20da%20insulina%20no%20sangue%202%20(0%2C6)%203%20(2%2C4)%203%20(1%2C3)%202%20(0%2C8)%201%20(0%2C4)%20%20Aumento%20da%20press%26%23xE3%3Bo%20arterial%202%20(0%2C6)%203%20(2%2C4)%201%20(0%2C4)%201%20(0%2C4)%203%20(1%2C2)%20%20Aumento%20de%20triglic%26%23xE9%3Brides%20no%20sangue%201%20(0%2C3)%202%20(1%2C6)%201%20(0%2C4)%200%200%20%20ECG%3A%20intervalo%20QT%20corrigido%20prolongado*%209%20(2%2C5)%204%20(3%2C1)%209%20(3%2C8)%207%20(2%2C8)%2012%20(5%2C0)%20%20ECG%3A%20onda%20T%20anormal%204%20(1%2C1)%203%20(2%2C4)%202%20(0%2C9)%204%20(1%2C6)%202%20(0%2C8)%20%20ECG%3A%20invers%26%23xE3%3Bo%20da%20onda%20T%203%20(0%2C8)%200%201%20(0%2C4)%203%20(1%2C2)%202%20(0%2C8)%20%20ECG%20anormal%200%200%200%204%20(1%2C6)%202%20(0%2C8)%20%20Aumento%20da%20frequ%26%23xEA%3Bncia%20card%26%23xED%3Baca%202%20(0%2C6)%204%20(3%2C1)%202%20(0%2C9)%201%20(0%2C4)%203%20(1%2C2)%20%20Aumento%20do%20pept%26%23xED%3Bdeo-C%20da%20insulina%203%20(0%2C8)%202%20(1%2C6)%203%20(1%2C3)%202%20(0%2C8)%200%20%20Redu%26%23xE7%3B%26%23xE3%3Bo%20do%20peso%203%20(0%2C8)%202%20(1%2C6)%200%200%200%20%20Aumento%20do%20peso%205%20(1%2C4)%201%20(0%2C8)%200%204%20(1%2C6)%204%20(1%2C7)%20%20Transtornos%20metab%26%23xF3%3Blicos%20e%20nutricionais%20%20Redu%26%23xE7%3B%26%23xE3%3Bo%20do%20apetite%200%202%20(1%2C6)%201%20(0%2C4)%201%20(0%2C4)%202%20(0%2C8)%20%20Aumento%20do%20apetite%201%20(0%2C3)%202%20(1%2C6)%200%203%20(1%2C2)%203%20(1%2C2)%20%20Transtornos%20m%26%23xFA%3Bsculo-esquel%26%23xE9%3Bticos%20%20e%20de%20tecido%20conjuntivo%20%20Artralgia%203%20(0%2C8)%200%204%20(1%2C7)%202%20(0%2C8)%200%20%20Lombalgia%203%20(0%2C8)%201%20(0%2C8)%202%20(0%2C9)%203%20(1%2C2)%205%20(2%2C1)%20%20Rigidez%20muscular%200%201%20(0%2C8)%200%203%20(1%2C2)%201%20(0%2C4)%20%20Dor%20no%20pesco%26%23xE7%3Bo%201%20(0%2C3)%200%200%200%203%20(1%2C2)%20%20Dor%20em%20extremidade%204%20(1%2C1)%200%202%20(0%2C9)%200%205%20(2%2C1)%20%20Dor%20no%20ombro%200%201%20(0%2C8)%203%20(1%2C3)%202%20(0%2C8)%202%20(0%2C8)%20%20Transtornos%20do%20sistema%20nervoso%20%20Acatisia%2014%20(3%2C9)%205%20(3%2C9)%207%20(3%2C0)%2020%20(8%2C1)%2023%20(9%2C5)%20%20Vertigem%2014%20(3%2C9)%207%20(5%2C5)%2011%20(4%2C7)%2011%20(4%2C5)%2012%20(5%2C0)%20%20Discinesia%203%20(0%2C8)%200%201%20(0%2C4)%201%20(0%2C4)%204%20(1%2C7)%20%20Distonia%20%202%20(0%2C6)%2001%20(0%2C8)%203%20(1%2C3)%209%20(3%2C7)%209%20(3%2C7)%20%20Transtorno%20extrapiramidal%208%20(2%2C3)%206%20(4%2C7)%205%20(2%2C1)%2017%20(6%2C9)%2018%20(7%2C4)%20%20Cefal%26%23xE9%3Bia%2042%20(11%2C8)%2014%20(11%2C0)%2029%20(12%2C3)%2034%20(13%2C8)%2035%20(14%2C5)%20%20Hipertonia%204%20(1%2C1)%203%20(2%2C4)%203%20(1%2C3)%2010%20(4%2C1)%208%20(3%2C3)%20%20Parkinsonismo%200%200%201%20(0%2C4)%205%20(2%2C0)%203%20(1%2C2)%20%20Seda%26%23xE7%3B%26%23xE3%3Bo%2013%20(3%2C7)%201%20(0%2C8)%2012%20(5%2C1)%208%20(3%2C3)%2015%20(6%2C2)%20%20Sonol%26%23xEA%3Bncia%2012%20(3%2C4)%206%20(4%2C7)%208%20(3%2C4)%2017%20(6%2C9)%2011%20(4%2C5)%20%20S%26%23xED%3Bncope%201%20(0%2C3)%201%20(0%2C8)%202%20(0%2C9)%203%20(1%2C2)%201%20(0%2C4)%20%20Tremor%2012%20(3%2C4)%204%20(3%2C1)%206%20(2%2C6)%2011%20(4%2C5)%208%20(3%2C3)%20%20Transtornos%20psiqui%26%23xE1%3Btricos%20%20Agressividade%204%20(1%2C1)%202%20(1%2C6)%201%20(0%2C4)%203%20(1%2C2)%202%20(0%2C8)%20%20Ansiedade%2029%20(8%2C2)%2012%20(9%2C4)%2016%20(6%2C8)%2014%20(5%2C7)%2011%20(4%2C5)%20%20Depress%26%23xE3%3Bo%201%20(0%2C3)%200%203%20(1%2C3)%201%20(0%2C4)%201%20(0%2C4)%20%20Pesadelos%200%200%201%20(0%2C4)%203%20(1%2C2)%201%20(0%2C4)%20%20Idea%26%23xE7%3B%26%23xE3%3Bo%20suicida%204%20(1%2C1)%202%20(1%2C6)%202%20(0%2C9)%201%20(0%2C4)%201%20(0%2C4)%20%20Transtornos%20respirat%26%23xF3%3Brio%2C%20tor%26%23xE1%3Bcico%20%20e%20mediast%26%23xED%3Bnico%20%20Tosse%204%20(1%2C1)%204%20(3%2C1)%204%20(1%2C7)%207%20(2%2C8)%204%20(1%2C7)%20%20Congest%26%23xE3%3Bo%20nasal%203%20(0%2C8)%201%20(0%2C8)%203%20(1%2C3)%202%20(0%2C8)%202%20(0%2C8)%20%20Transtornos%20de%20pele%20e%20de%20tecido%20subcut%26%23xE2%3Bneo%20%20Prurido%204%20(1%2C1)%200%203%20(1%2C3)%202%20(0%2C8)%200%20%20Transtornos%20vasculares%20%20Hipotens%26%23xE3%3Bo%201%20(0%2C3)%202%20(1%2C6)%201%20(0%2C4)%202%20(0%2C8)%202%20(0%2C8)%20%20Hipotens%26%23xE3%3Bo%20ostost%26%23xE1%3Btica%203%20(0%2C8)%203%20(2%2C4)%203%20(1%2C3)%206%20(2%2C4)%209%20(3%2C7)%20%20*%20Quando%20foi%20aplicado%20um%20fator%20de%20corre%26%23xE7%3B%26%23xE3%3Bo%20apropriado%2C%20QTc%20linear%20derivado%2C%20n%26%23xE3%3Bo%20houve%20%20casos%20de%20prolongamento%20de%20QTc.%20%20Dados%20de%20estudos%20cl%26%23xED%3Bnicos%3A%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20ao%20f%26%23xE1%3Brmaco%20em%20estudos%20%20de%20curta-dura%26%23xE7%3B%26%23xE3%3Bo%2C%20com%20dose-fi%20xa%2C%20controlados%20com%20placebo.%20%20As%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20mais%20frequentes%2C%20relatadas%20por%20%3D%202%25%20dos%20pacientes%20tratados%20%20com%20Invega%20inclu%26%23xED%3Bram%3A%20cefal%26%23xE9%3Bia%20(13%2C2%25)%2C%20taquicardia%20(6%2C6%25)%2C%20acatisia%20%20(6%2C5%25)%2C%20taquicardia%20sinusal%20(5%2C5%25)%2C%20transtorno%20extrapiramidal%20(5%2C4%25)%2C%20sonol%26%23xEA%3Bncia%20%20(4%2C9%25)%2C%20vertigem%20(4%2C8%25)%2C%20seda%26%23xE7%3B%26%23xE3%3Bo%20(4%2C2%25)%2C%20tremor%20(3%2C4%25)%2C%20hipertonia%20%20(2%2C8%25)%2C%20distonia%20(2%2C6%25)%2C%20hipotens%26%23xE3%3Bo%20ortost%26%23xE1%3Btica%20(2%2C5%25)%20e%20boca%20seca%20(2%2C4%25).%20%20As%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20que%20parecem%20estar%20relacionadas%20%26%23xE0%3B%20dose%20foram%3A%20aumento%20%20do%20peso%2C%20cefal%26%23xE9%3Bia%2C%20hipersecre%26%23xE7%3B%26%23xE3%3Bo%20salivar%2C%20v%26%23xF4%3Bmito%2C%20discinesia%2C%20acatisia%2C%20%20distonia%2C%20transtorno%20extrapiramidal%2C%20hipertonia%20e%20Parkinsonismo.%20%20As%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20descritas%20a%20seguir%20foram%20relatadas%20pelos%20pacientes%20%20com%20esquizofrenia%2C%20tratados%20com%20Invega%20(n%3D850)%20nos%203%20estudos%20cl%26%23xED%3Bnicos%20%20de%20dose%20fi%20xa%2C%20duplo-cegos%2C%20controlados%20por%20placebo%2C%20de%206%20semanas%20de%20dura%26%23xE7%3B%26%23xE3%3Bo.%20%20Os%20seguintes%20termos%20e%20frequ%26%23xEA%3Bncias%20foram%20aplicados%3A%20muito%20comum%20%20(%3D10%25)%2C%20comum%20(frequente)%20(%3D1%25%20a%20%26lt%3B10%25)%2C%20incomum%20(infrequente)%20(%3D0%2C1%25%20%20a%20%26lt%3B1%25)%2C%20raro%20(%3D0%2C01%25%20a%20%26lt%3B0%2C1%25)%20e%20muito%20raro%20(%26lt%3B0%2C01%25).%20A%20maioria%20dos%20eventos%20%20adversos%20foram%20de%20gravidade%20leve%20a%20moderada.%20%20Avalia%26%23xE7%3B%26%23xF5%3Bes%3A%20comum%3A%20aumento%20de%20peso%3B%20incomum%3A%20eletrocardiograma%20%20anormal.%20%20Transtornos%20card%26%23xED%3Bacos%3A%20comum%3A%20taquicardia%20sinusal%2C%20taquicardia%20atrioventricular%2C%20%20bloqueio%20de%20primeiro%20grau%2C%20bloqueio%20de%20ramo%2C%20bradicardia%3B%20incomum%3A%20%20palpita%26%23xE7%3B%26%23xF5%3Bes%2C%20arritmia%20sinusal.%20%20Transtornos%20oculares%3A%20incomum%3A%20rota%26%23xE7%3B%26%23xE3%3Bo%20ocular.%20%20Transtornos%20gastrintestinais%3A%20comum%3A%20dor%20abdominal%20alta%2C%20boca%20seca%2C%20hipersecre%26%23xE7%3B%26%23xE3%3Bo%20%20salivar%2C%20v%26%23xF4%3Bmito.%20%20Transtornos%20gerais%3A%20comum%3A%20astenia%2C%20fadiga%3B%20incomum%3A%20edema.%20%20Transtornos%20do%20sistema%20imunol%26%23xF3%3Bgico%3A%20incomum%3A%20rea%26%23xE7%3B%26%23xE3%3Bo%20anafi%20l%26%23xE1%3Btica.%20%20Transtornos%20metab%26%23xF3%3Blicos%20e%20nutricionais%3A%20incomum%3A%20aumento%20do%20apetite%20%20Transtornos%20de%20m%26%23xFA%3Bsculo-esquel%26%23xE9%3Btico%20e%20de%20tecido%20conjuntivo%3A%20incomum%3A%20%20rigidez%20muscular.%20%20Transtornos%20do%20sistema%20nervoso%3A%20muito%20comum%3A%20cefal%26%23xE9%3Bia%3B%20comum%3A%20acatisia%2C%20%20vertigem%2C%20distonia%2C%20transtorno%20extrapiramidal%2C%20hipertonia%2C%20Parkinsonismo%2C%20%20seda%26%23xE7%3B%26%23xE3%3Bo%2C%20sonol%26%23xEA%3Bncia%2C%20tremor%3B%20incomum%3A%20vertigem%20postural%2C%20discinesia%2C%20%20convuls%26%23xE3%3Bo%20do%20tipo%20grande%20mal%2C%20s%26%23xED%3Bncope.%20%20Transtorno%20psiqui%26%23xE1%3Btrico%3A%20incomum%3A%20pesadelo.%20%20Transtorno%20do%20sistema%20reprodutor%20e%20de%20mamas%3A%20incomum%3A%20amenorr%26%23xE9%3Bia%2C%20%20secre%26%23xE7%3B%26%23xE3%3Bo%20mam%26%23xE1%3Bria%2C%20disfun%26%23xE7%3B%26%23xE3%3Bo%20er%26%23xE9%3Btil%2C%20galactorr%26%23xE9%3Bia%2C%20ginecomastia%2C%20menstrua%26%23xE7%3B%26%23xE3%3Bo%20%20irregular.%20%20Transtornos%20vasculares%3A%20comum%3A%20hipotens%26%23xE3%3Bo%20ortost%26%23xE1%3Btica%3B%20incomum%3A%20hipotens%26%23xE3%3Bo%2C%20%20isquemia.%20%20Pacientes%20idosos%20%20A%20seguran%26%23xE7%3Ba%20de%20Invega%20foi%20avaliada%20em%2081%20pacientes%20idosos%20com%20esquizofrenia%20%20(idade%20%3D65%20anos)%20que%20receberam%20doses%20fl%20ex%26%23xED%3Bveis%20(n%3D76)%20ou%20fi%20xas%20%20(n%3D5)%20de%20Invega%20na%20faixa%20de%203%20a%2012%20mg%20uma%20vez%20ao%20dia%20por%20at%26%23xE9%3B%206%20semanas%20durante%20os%20estudos%20duplo-cegos%2C%20controlados%20com%20placebo.%20Embora%20esse%20%20conjunto%20de%20dados%20n%26%23xE3%3Bo%20permita%20uma%20compara%26%23xE7%3B%26%23xE3%3Bo%20direta%20sistem%26%23xE1%3Btica%20entre%20%20pacientes%20idosos%20e%20n%26%23xE3%3Bo%20idosos%2C%20o%20perfi%20l%20de%20seguran%26%23xE7%3Ba%20foi%20similar%20nas%20duas%20%20popula%26%23xE7%3B%26%23xF5%3Bes.%20No%20entanto%2C%20com%20base%20nesses%20dados%20limitados%20e%20consistente%20%20com%20a%20pr%26%23xE1%3Btica%20cl%26%23xED%3Bnica%20geral%2C%20n%26%23xE3%3Bo%20%26%23xE9%3B%20poss%26%23xED%3Bvel%20excluir%20uma%20maior%20sensibilidade%20%20de%20indiv%26%23xED%3Bduos%20mais%20idosos%20a%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas.%20%20Eventos%20de%20interesse%20particular%20para%20a%20classe%20%20Sintomas%20extrapiramidais%3A%20os%20dados%20agrupados%20dos%203%20estudos%20cl%26%23xED%3Bnicos%20de%20%20dose%20fi%20xa%2C%20controlados%20com%20placebo%2C%20de%206%20semanas%20de%20dura%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20revelaram%20%20diferen%26%23xE7%3Bas%20nos%20eventos%20extrapiramidais%20que%20surgiram%20com%20o%20tratamento%2C%20%20comparando-se%20o%20placebo%20(11%25)%20e%20Invega%203%20e%206%20mg%20(13%25%20e%2010%25%2C%20%20respectivamente).%20Sintomas%20extrapiramidais%20relacionados%20%26%23xE0%3B%20dose%20foram%20%20observados%20nas%20duas%20dosagens%20maiores%20de%20Invega%20(25%25%20e%2026%25%20para%20%20as%20doses%20de%209%20e%2012%20mg%2C%20respectivamente).%20Os%20sintomas%20extrapiramidais%20%20inclu%26%23xED%3Bram%20uma%20an%26%23xE1%3Blise%20agrupada%20dos%20seguintes%20termos%3A%20discinesia%2C%20distonia%2C%20%20hipercinesia%2C%20Parkinsonismo%20e%20tremor.%20%20Ganho%20de%20peso%3A%20nos%20dados%20agrupados%20dos%203%20estudos%20cl%26%23xED%3Bnicos%20de%20dose%20fi%20xa%2C%20%20controlados%20com%20placebo%2C%20de%206%20semanas%20de%20dura%26%23xE7%3B%26%23xE3%3Bo%2C%20as%20propor%26%23xE7%3B%26%23xF5%3Bes%20de%20%20pacientes%20que%20atingiram%20o%20crit%26%23xE9%3Brio%20de%20ganho%20de%20peso%20%3D7%25%20do%20peso%20corporal%20%20foram%20comparadas%20e%20revelaram%20uma%20incid%26%23xEA%3Bncia%20similar%20de%20ganho%20de%20peso%20%20para%20Invega%203%20mg%20(7%25)%20e%206%20mg%20(6%25)%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20ao%20placebo%20(5%25)%20e%20%20uma%20maior%20incid%26%23xEA%3Bncia%20de%20ganho%20de%20peso%20para%209%20mg%20(9%25)%20e%2012%20mg%20(9%25).%20%20Exames%20laboratoriais%3A%20Prolactina%20s%26%23xE9%3Brica%3A%20com%20base%20nos%20dados%20agrupados%20%20dos%203%20estudos%20cl%26%23xED%3Bnicos%20de%20dose%20fi%20xa%2C%20controlados%20com%20placebo%2C%20de%206%20semanas%20%20de%20dura%26%23xE7%3B%26%23xE3%3Bo%2C%20foram%20observados%20aumentos%20medianos%20na%20prolactina%20%20s%26%23xE9%3Brica%20em%20pacientes%20de%20ambos%20os%20sexos%20que%20receberam%20Invega.%20Os%20%20aumentos%20m%26%23xE9%3Bdios%20m%26%23xE1%3Bximos%20da%20concentra%26%23xE7%3B%26%23xE3%3Bo%20de%20prolactina%20s%26%23xE9%3Brica%20foram%20%20observados%2C%20em%20geral%2C%20no%2015%26%23xBA%3B%20dia%20do%20tratamento%2C%20mas%20permaneceram%20acima%20%20dos%20n%26%23xED%3Bveis%20da%20linha%20de%20base%20ao%20fi%20nal%20do%20estudo.%20%20Estudos%20Cl%26%23xED%3Bnicos%3A%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20%26%23xE0%3B%20droga%20em%20estudo%20de%20longa-dura%26%23xE7%3B%26%23xE3%3Bo%2C%20%20controlado%20por%20placebo%3A%20a%20seguran%26%23xE7%3Ba%20de%20Invega%20foi%20tamb%26%23xE9%3Bm%20avaliada%20em%20%20estudo%20de%20longa-dura%26%23xE7%3B%26%23xE3%3Bo%2C%20delineado%20para%20avaliar%20manuten%26%23xE7%3B%26%23xE3%3Bo%20do%20efeito%20de%20%20Invega%20em%20adultos%20com%20esquizofrenia.%20Em%20geral%2C%20os%20tipos%2C%20freq%26%23xFC%3B%26%23xEA%3Bncias%20e%20%20gravidades%20das%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20%26%23xE0%3B%20droga%2C%20relatados%20durante%20a%20fase%20inicial%2C%20%20aberta%2C%20de%2014%20semanas%20deste%20estudo%2C%20foram%20compar%26%23xE1%3Bveis%20%26%23xE0%3B%20aqueles%20relatados%20%20no%20estudo%20de%20curto%20prazo%2C%20por%2006%20semanas%2C%20com%20dose-fi%20xa%2C%20controlado%20%20por%20placebo.%20As%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20%26%23xE0%3B%20droga%20relatadas%20durante%20a%20fase%20de%20%20longo%20prazo%2C%20duplo-cega%20deste%20estudo%20foram%20similares%20em%20tipo%20e%20gravidade%20%20%26%23xE0%3Bs%20observadas%20na%20fase%20aberta%2C%20inicial%2C%20com%20dura%26%23xE7%3B%26%23xE3%3Bo%20de%2014%20semanas%3B%20entretanto%2C%20%20em%20geral%20ocorreram%20em%20freq%26%23xFC%3B%26%23xEA%3Bncias%20menores.%20%20Informa%26%23xE7%3B%26%23xF5%3Bes%20de%20seguran%26%23xE7%3Ba%20relacionados%20%26%23xE0%3B%20risperidona%3A%20a%20paliperidona%20corresponde%20%20a%20um%20metab%26%23xF3%3Blito%20ativo%20da%20risperidona.%20O%20perfi%20l%20de%20libera%26%23xE7%3B%26%23xE3%3Bo%20da%20%20droga%20e%20as%20propriedades%20farmacocin%26%23xE9%3Bticas%20de%20Invega%20s%26%23xE3%3Bo%20consideralvemente%20%20diferentes%20das%20observadas%20com%20formula%26%23xE7%3B%26%23xF5%3Bes%20de%20libera%26%23xE7%3B%26%23xE3%3Bo%20imediata%2C%20para%20admnistra%26%23xE7%3B%26%23xE3%3Bo%20via%20oral%2C%20contendo%20risperidona.%20As%20informa%26%23xE7%3B%26%23xF5%3Bes%20de%20seguran%26%23xE7%3Ba%20%20relatadas%20com%20risperidona%20em%20estudos%20cl%26%23xED%3Bnicos%20e%20em%20experi%26%23xEA%3Bncia%20%20p%26%23xF3%3Bs-comercializa%26%23xE7%3B%26%23xE3%3Bo%20que%20n%26%23xE3%3Bo%20foram%20relatadas%20com%20Invega%20podem%20ser%20%20encontradas%20na%20bula%20de%20medicamentos%20contendo%20risperidona.%0A%0A%0A%0A%3C%2Fp%3E%3Ch2%3EINVEGA%20%26%23x2013%3B%20Posologia%3C%2Fh2%3E%0A%3Cp%3EAdultos%20(idade%20acima%20de%2018%20anos)%20%20A%20dose%20de%20Invega%20recomendada%20%26%23xE9%3B%20de%206%20mg%20uma%20vez%20ao%20dia%2C%20por%20via%20oral%2C%20%20administrado%20pela%20manh%26%23xE3%3B%20com%20ou%20sem%20alimentos.%20N%26%23xE3%3Bo%20%26%23xE9%3B%20necess%26%23xE1%3Brio%20titular%20%20a%20dose%20inicial.%20Alguns%20pacientes%20podem%20se%20benefi%20ciar%20de%20doses%20mais%20altas%20%20ou%20mais%20baixas%20dentro%20da%20faixa%20recomendada%20de%203%20a%2012%20mg%20uma%20vez%20ao%20dia.%20%20Se%20indicados%2C%20os%20ajustes%20da%20dose%20podem%20ser%20feitos%20ap%26%23xF3%3Bs%20reavalia%26%23xE7%3B%26%23xE3%3Bo%20cl%26%23xED%3Bnica.%20%20Quando%20aumentos%20de%20dose%20s%26%23xE3%3Bo%20indicados%2C%20recomenda-se%20aumentos%20de%203%20%20mg%2Fdia%20e%20devem%20geralmente%20ocorrer%20em%20intervalos%20maiores%20do%20que%205%20dias.%20%20Pacientes%20com%20insufi%20ci%26%23xEA%3Bncia%20hep%26%23xE1%3Btica%20%20N%26%23xE3%3Bo%20%26%23xE9%3B%20necess%26%23xE1%3Brio%20ajustar%20a%20dose%20em%20pacientes%20com%20insufi%20ci%26%23xEA%3Bncia%20hep%26%23xE1%3Btica%20%20leve%20%26%23xE0%3B%20moderada.%20Invega%20n%26%23xE3%3Bo%20foi%20estudado%20em%20pacientes%20com%20insufi%20ci%26%23xEA%3Bncia%20%20hep%26%23xE1%3Btica%20grave.%20%20Pacientes%20com%20insufi%20ci%26%23xEA%3Bncia%20renal%20%20Para%20pacientes%20com%20insufi%20ci%26%23xEA%3Bncia%20renal%20leve%20(depura%26%23xE7%3B%26%23xE3%3Bo%20da%20creatinina%20%3D50%20a%20%20%26lt%3B%2080%20mL%2Fmin)%2C%20a%20dose%20inicial%20recomendada%20%26%23xE9%3B%203%20mg%20uma%20vez%20ao%20dia.%20A%20dose%20%20pode%20ser%20aumentada%20para%206%20mg%20uma%20vez%20ao%20dia%20baseados%20na%20tolerabilidade%20%20e%20resposta%20cl%26%23xED%3Bnica.%20%20Para%20pacientes%20com%20insufi%20ci%26%23xEA%3Bncia%20renal%20moderada%20a%20grave%20(depura%26%23xE7%3B%26%23xE3%3Bo%20da%20%20creatinina%20%3D10%20a%20%26lt%3B%2050%20mL%2Fmin)%2C%20a%20dose%20recomendada%20%26%23xE9%3B%203%20mg%20uma%20vez%20ao%20%20dia.%20Como%20Invega%20n%26%23xE3%3Bo%20foi%20estudado%20em%20pacientes%20com%20depura%26%23xE7%3B%26%23xE3%3Bo%20de%20%20creatinina%20%26lt%3B%2010%20mL%2Fmin%20%2C%20n%26%23xE3%3Bo%20se%20recomenda%20o%20uso%20nestes%20pacientes.%20%20Pacientes%20idosos%20%20As%20recomenda%26%23xE7%3B%26%23xF5%3Bes%20posol%26%23xF3%3Bgicas%20para%20pacientes%20idosos%20com%20fun%26%23xE7%3B%26%23xE3%3Bo%20renal%20%20normal%20(%3D%2080%20mL%2Fmin)%20s%26%23xE3%3Bo%20as%20mesmas%20que%20as%20para%20adultos%20com%20fun%26%23xE7%3B%26%23xE3%3Bo%20renal%20%20normal.%20No%20entanto%2C%20como%20os%20pacientes%20idosos%20podem%20ter%20fun%26%23xE7%3B%26%23xE3%3Bo%20renal%20%20diminu%26%23xED%3Bda%2C%20pode%20ser%20necess%26%23xE1%3Brio%20ajustar%20a%20dose%20de%20acordo%20com%20o%20estado%20da%20%20fun%26%23xE7%3B%26%23xE3%3Bo%20renal.%20%20Crian%26%23xE7%3Bas%20%20A%20seguran%26%23xE7%3Ba%20e%20a%20efi%20c%26%23xE1%3Bcia%20de%20Invega%20n%26%23xE3%3Bo%20foram%20avaliadas%20em%20pacientes%20%20com%20idade%20inferior%20a%2018%20anos.%20%20Outras%20popula%26%23xE7%3B%26%23xF5%3Bes%20especiais%20%20N%26%23xE3%3Bo%20h%26%23xE1%3B%20recomenda%26%23xE7%3B%26%23xE3%3Bo%20para%20ajuste%20da%20dose%20de%20Invega%20em%20fun%26%23xE7%3B%26%23xE3%3Bo%20do%20%20sexo%2C%20ra%26%23xE7%3Ba%20ou%20tabagismo.%0A%0A%0A%0A%3C%2Fp%3E%3Ch2%3ESuper%20dosagem%3C%2Fh2%3E%0A%3Cp%3ESintomas%20%20Em%20geral%2C%20os%20sinais%20e%20sintomas%20esperados%20s%26%23xE3%3Bo%20aqueles%20resultantes%20de%20uma%20%20exacerba%26%23xE7%3B%26%23xE3%3Bo%20dos%20efeitos%20farmacol%26%23xF3%3Bgicos%20conhecidos%20da%20paliperidona%2C%20isto%20%20%26%23xE9%3B%2C%20sonol%26%23xEA%3Bncia%20e%20seda%26%23xE7%3B%26%23xE3%3Bo%2C%20taquicardia%20e%20hipotens%26%23xE3%3Bo%2C%20prolongamento%20QT%20e%20%20sintomas%20extrapiramidais.%20No%20caso%20de%20superdose%20aguda%2C%20a%20possibilidade%20%20de%20envolvimento%20de%20v%26%23xE1%3Brios%20f%26%23xE1%3Brmacos%20deve%20ser%20considerada.%20%20Tratamento%20%20Ao%20avaliar%20a%20necessidade%20de%20tratamento%20e%20a%20recupera%26%23xE7%3B%26%23xE3%3Bo%20deve-se%20considerar%20%20a%20natureza%20da%20libera%26%23xE7%3B%26%23xE3%3Bo%20prolongada%20do%20medicamento.%20N%26%23xE3%3Bo%20h%26%23xE1%3B%20ant%26%23xED%3Bdoto%20%20espec%26%23xED%3Bfi%20co%20para%20a%20paliperidona.%20Medidas%20gerais%20de%20suporte%20devem%20%20ser%20adotadas.%20Estabelecer%20e%20manter%20as%20vias%20a%26%23xE9%3Breas%20e%20garantir%20oxigena%26%23xE7%3B%26%23xE3%3Bo%20%20e%20ventila%26%23xE7%3B%26%23xE3%3Bo%20adequadas.%20O%20monitoramento%20cardiovascular%20deve%20ser%20iniciado%20%20imediatamente%20e%20deve%20incluir%20monitoramento%20eletrocardiogr%26%23xE1%3Bfico%20cont%26%23xED%3Bnuo%20para%20poss%26%23xED%3Bveis%20arritmias.%20Hipotens%26%23xE3%3Bo%20e%20colapso%20circulat%26%23xF3%3Brio%20devem%20%20ser%20tratados%20com%20medidas%20apropriadas%20tais%20como%20l%26%23xED%3Bquidos%20intravenosos%20e%2F%20%20ou%20agentes%20simpatomim%26%23xE9%3Bticos.%20A%20lavagem%20g%26%23xE1%3Bstrica%20(ap%26%23xF3%3Bs%20intuba%26%23xE7%3B%26%23xE3%3Bo%20se%20o%20%20paciente%20estiver%20inconsciente)%20e%20a%20administra%26%23xE7%3B%26%23xE3%3Bo%20de%20carv%26%23xE3%3Bo%20ativado%20junto%20%20com%20um%20laxativo%20devem%20ser%20consideradas.%20Na%20presen%26%23xE7%3Ba%20de%20sintomas%20extrapiramidais%20%20graves%2C%20agentes%20anticolin%26%23xE9%3Brgicos%20devem%20ser%20administrados.%20%20Uma%20supervis%26%23xE3%3Bo%20cuidadosa%20e%20o%20monitoramento%20devem%20continuar%20at%26%23xE9%3B%20a%20recupera%26%23xE7%3B%26%23xE3%3Bo%20do%20paciente.%3C%2Fp%3E%0A%3Ch2%3ECaracteristicas%20farmalogicas%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%20%20%20%20%20%20%20%20%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%20%20%20%20%20%20%20%20%20%20%20%20%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%20%20%20%20%20%20%20%20%3C%2Famp-ad%3E%0A%3Ch2%3EResultados%20de%20eficacia%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%3Ch2%3EUsos%20em%20idosos%2C%20crian%26%23xE7%3Bas%20e%20em%20outros%20grupos%20de%20risco%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%3Ch2%3EArmazenagem%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%3Ch2%3EDizeres%20legais%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%20%20%20%20%20%20%20%20%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%20%20%20%20%20%20%20%20%20%20%20%20%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%20%20%20%20%20%20%20%20%3C%2Famp-ad%3E%0A%3Ch2%3EINVEGA%20%26%23x2013%3B%20Bula%20para%20o%20paciente%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%3Ch2%3EData%20da%20bula%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%09%09%09%09%09%09
- Ame
- Sim
- ApresentarPrecoDePor
- Sim
- custom_label_0
- campanha
- MedicamentoControlado
- Sim
- Cashback
- Não
- Antibiotico
- Não
- Generico
- Não
Tributos e contexto fiscal
Preferência salva neste navegador; confirme o destino da operação.
NCM, CEST e tributos são referências fiscais brasileiras e podem não se aplicar em outros países.
Selecione a UF nesta seção para consultar a estimativa IBPT.
IBS/CBS: depende da operação, regime, data, destino e documento fiscal. Percentuais e CST/cClassTrib indisponíveis sem esse contexto.
